21 completed. 21 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 21 | Completed 21 |
Follow Zika Virus Infection: new trials by email Literature Review of Zika Virus Infection trials Research Report on Zika Virus Infection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of the Protective Efficacy of TV003 or Previous Zika Infection Against Infection With ZIKV-SJRP Challenge Compared to DENV and ZIKV-naïve Controls Against Infection With ZIKV-SJRP Challenge TetraVax-DV-TV003 (TV003), Plasmalyte, Challenge virus ZIKV-SJRP/2016-184 - Zika Virus | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 27 | 2024-09-24 | 2026-03-09 |
| Phase 1 Trial to Assess the Safety and Immunogenicity of an Inactivated, Adjuvanted Whole Zika Virus Vaccine Candidate (VLA1601) in Healthy Adults VLA1601, CpG 1018®, 3M-052-AF - Zika, Zika Virus Infection | Phase 1 | Completed | Valneva Austria GmbH | 150 | 2024-03-25 | 2026-03-09 |
| Evaluation of Two Zika Viruses for Use in Controlled Human Infection Models (CHIM) ZIKV-SJRP/2016-184 Strain, Experimental: ZIKV-Nicaragua/2016 Strain, Placebo - Zika Virus | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 56 | 2022-02-16 | 2025-04-11 |
| Research Study to Assess New Chikungunya and Zika Vaccines in Healthy Adults in Mexico. CHIK low dose, CHIK mid dose, CHIK high dose - Chikungunya, Zika | Phase 1 | Completed | University of Oxford | 120 | 2020-10-23 | 2022-03-23 |
| Safety and Immunogenicity of a Candidate ZIKV Vaccine (ZIKA001) ChAdOx1 Zika - Zika | Phase 1 | Completed | University of Oxford | 24 | 2019-10-21 | 2022-05-18 |
| Safety and Immunogenicity of a Novel Vaccine Formulation MV-ZIKA-RSP (V187-001) Two MV-ZIKA-RSP vaccinations (high dose), Two MV-ZIKA-RSP vaccination (low dose), One MV-ZIKA-RSP vaccination (high dose) and one placebo - Zika Virus Infection | Phase 1 | Completed | Themis Bioscience GmbH | 48 | 2019-08-02 | 2021-12-06 |
| Safety, Tolerability, and Immunogenicity of Zika Vaccine mRNA-1893 in Healthy Flavivirus Seropositive and Seronegative Adults mRNA-1893, Placebo - Zika Virus | Phase 1 | Completed | ModernaTX, Inc. | 120 | 2019-07-30 | 2024-08-21 |
| Safety and Immunogenicity of the Live Attenuated Zika Vaccine rZIKV/D4Δ30-713 in Flavivirus-naïve Adults Single dose of rZIKV/D4Δ30-713 (10^3 PFU) via subcutaneous injection (0.5ml), Single dose of placebo via subcutaneous injection (0.5ml)., Single dose of rZIKV/D4Δ30-713 (10^4 PFU) via subcutaneous injection (0.5ml) - Zika Virus | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 56 | 2018-07-06 | 2025-08-05 |
| Study in Healthy Volunteers Evaluating Safety and Pharmacokinetics of Zika Virus Immune Globulin (ZIKV-IG) Zika Virus Immune Globulin (ZIKV-IG), Placebo - Zika Virus Infection, Zika Virus Disease | Phase 1 | Completed | Emergent BioSolutions | 30 | 2018-06-27 | 2024-03-18 |
| Randomized, Placebo-controlled, Observer-blinded Phase 1 Safety and Immunogenicity Study of Inactivated Zika Virus Vaccine Candidate in Healthy Adults VLA1601, Placebo - Zika Virus, Zika Virus Infection | Phase 1 | Completed | Valneva Austria GmbH | 67 | 2018-02-24 | 2019-07-05 |
| Safety and Tolerability of an Antibody Against Zika Virus (Tyzivumab) in Humans Tyzivumab - Treatment of Acute Zika Virus Infection | Phase 1 | Completed | Tychan Pte Ltd. | 24 | 2018-02-08 | 2019-04-10 |
| Safety, Immunogenicity, and Dose Ranging Study of Inactivated Zika Virus Vaccine in Healthy Participants Placebo, PIZV - Virus, Zika, Zika Virus Disease | Phase 1 | Completed | Takeda | 271 | 2017-11-13 | 2022-02-11 |
| Safety and Immunogenicity of BBV121 BBV121 - Zika Virus Infection | Phase 1 | Completed | Bharat Biotech International Limited | 48 | 2017-06-03 | 2020-10-22 |
| Zika-Vaccine Dose Finding Study Regarding Safety, Immunogenicity and Tolerability (V186-001) MV-ZIKA, Placebo - Zika Virus | Phase 1 | Completed | Themis Bioscience GmbH | 48 | 2017-05-03 | 2022-08-18 |
| Phase I, Randomized, Double-blinded, Placebo-Controlled Dose De-escalation Study to Evaluate Safety and Immunogenicity of Alum Adjuvanted Zika Virus Purified Inactivated Vaccine (ZPIV) in Adults in a Flavivirus Endemic Area Placebo, Zika Virus Purified Inactivated Vaccine (ZPIV) - Zika Virus Infection | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 91 | 2017-03-21 | 2023-04-06 |
| Safety, Tolerability, and Immunogenicity of mRNA-1325 in Healthy Adult Subjects mRNA-1325, Placebo - Zika Virus | Phase 1 | Completed | ModernaTX, Inc. | 90 | 2016-12-21 | 2024-08-21 |
| Zika Virus Purified Inactivated Vaccine (ZPIV) Accelerated Vaccination Schedule Study Zika Virus Purified Inactivated Vaccine, Placebo - Zika | Phase 1 | Completed | Kathryn Stephenson | 36 | 2016-12-08 | 2018-08-23 |
| A Phase 1, First-in-human, Double-blinded, Randomized, Placebo-controlled Trial of a Zika Virus Purified Inactivated Vaccine (ZPIV) With Alum Adjuvant in Healthy Flavivirus-naive and Flavivirus-Primed Subjects. IXIARO, Placebo, YF Vax 17D Strain - Zika Virus Infection | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 75 | 2016-11-01 | 2024-04-22 |
| ZIKA Vaccine in Naive Subjects Saline, Zika Virus Purified Inactivated Vaccine (ZPIV) - Zika Virus Infection | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 91 | 2016-10-14 | 2025-07-29 |
| GLS-5700 in Dengue Virus Seropositive Adults GLS-5700, Placebo - Healthy, Zika | Phase 1 | Completed | GeneOne Life Science, Inc. | 160 | 2016-08-01 | 2022-01-20 |
Showing 20 of 21. Sign in to see all of them.
Chikungunya Fever (1) · Communicable Diseases (1) · Flavivirus Infections (1) · Virus Diseases (1)
Arbovirus Infections (21) · Flaviviridae Infections (21) · Infections (21) · Mosquito-Borne Diseases (21) · RNA Virus Infections (21) · Vector Borne Diseases (21) · Flavivirus Infections (20) · Virus Diseases (20) · Alphavirus Infections (1) · Disease Attributes (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1) · Togaviridae Infections (1)
GLS-5700 vaccine (2) · 1018 oligonucleotide (1) · Plasmalyte A (1) · Saline Solution (1) · Sodium Chloride (1)
National Institute of Allergy and Infectious Diseases (NIAID) (6) · GeneOne Life Science, Inc. (2) · ModernaTX, Inc. (2) · Themis Bioscience GmbH (2) · University of Oxford (2) · Valneva Austria GmbH (2) · Bharat Biotech International Limited (1) · Emergent BioSolutions (1) · Kathryn Stephenson (1) · Takeda (1) · Tychan Pte Ltd. (1)
United States (12) · Puerto Rico (4) · Austria (2) · Canada (2) · India (1) · Mexico (1) · Singapore (1) · United Kingdom (1)
Anna Durbin, MD (2) · Adrian V Hill, DPhill FRCP (1) · Anna Durbin, M.D. (1) · Jenny Low, MBBS (1) · Joel Maslow, MD (1) · Katrin Dubischar (1) · Kristen Pierce, MD (1) · Michael McDonnell, MD (1) · Sudhakar Bangera (1) · Vadim Dreyzin, MD (1)
PMID 29217375, PMID 36682364, PMID 31053842, PMID 32618279, PMID 34019802, PMID 34525286, PMID 34610572, PMID 36484441, PMID 37390836
2016 (1), 2019 (1)